Cite
HARVARD Citation
Sandborn, W. et al. (n.d.). DOP52 Reduction in inflammatory biomarkers in a Phase 2 study of mirikizumab in patients with moderately to severely active ulcerative colitis. Journal of Crohn's and colitis. pp. S059-S060. [Online].